http://www.evrs.eu/medias/2010/congress/Branch-Retinal-Vein-Occlusion-Central-Retinal-Vein-Occlusion.flv

Michael Koss, M. Pfister, F. Rothweiler, M.  Michaelis, J.  Cinati, Pankaj Singh, Frank Koch (Frankfurt am Main, Germany)

Advantages:

To determine the levels of intravitreal VEGF A, monocytic adhesion protein = MCP, and IL-6 levels in retinal vein obstruction over a clinical observation time.

Methods:

Twelve patients with central retinal vein obstruction (CRVO) (70.3 years, 5 male), and 16 with branch retinal vein obstruction (BRVO) (73 male, 6 male) underwent 0.5 to 1ml core pars plana vitrectomy (cppV) with substitution of 1.25mg bevacizumab and 800µg dexamthasone as a first line combined treatment to treat ME (macular edema). The levels of VEGF, IL-6, and MCP were examined with cytometric bead assay (CBA) from the aspired cut vitreous specimen (T1). Retreatment was conducted on clinical relevant increase in CMT (central macular thickness) and BCVA (best corrected visual acuity) decrease (T2).

Effectiveness / Safety:

Vitreous VEGF levels measured with CBA yielded in CRVO VEGF levels of 206.2pg/ml and 76.8 (T1 to T2 = 34 weeks), IL-6 130.7 and 46.8, MCP 1040.4 and 657.1, whereas BRVO had VEGF of 159.8 and 130.7 (T1 to T2 = 41 weeks), Il-6 of 21.1 and 17.5, and MCP of 575.2 and 513.1.

Take home message:

The cytometric bead assay technique allows for a fast determination of vitreous levels of growth factors that indicate the outbalanced pathogenesis of angiogenesis (VEGF A) and inflammation (Il-6 and MCP). In general we could demonstrate higher vitreous levels at T1 in comparison to T2.